As recently reported, children having T cell-depleted peripheral blood stem cell transplantation (PBSCT) might be at increased risk for the development of drug resistance. To investigate if delayed immune recovery was a potential risk factor, the recovery of the CD3 + , CD4 + , CD8 + and CD19 
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+ blood stem cells
Studies in AIDS patients made clear that ganciclovir (GCV) resistance develops in a slow but progressive manner. GCV-resistant human cytomegalovirus (HCMV) seems to infect immunocompromised patients who have either profound immunosuppression with very high viral loads or who have undergone long periods of therapy. 1 Until recently, there have been only scattered reports of GCV resistance in transplant recipients. As reported, in a study of 240 allograft recipients, subsets at special risk were HCMV-seronegative patients who received an organ from an HCMV-seropositive donor and those patients who required long periods of intense immunosuppression. On average, the patients in this report were treated with GCV for a mean of 190 days, which suggested that the duration of GCV exposure is also an important factor in the development of resistance. 2 In the BMT setting, there is even less knowledge about GCV resistance. After BMT in adults there exists to date only one report about a patient with phenotypic, as well as genotypic GCV resistance, 3 whereas a recent study using RFLP analysis limited to the detection of some frequent occurring UL97 mutations (codons: 460, 520, 594, 595) did not reveal any evidence for the emergence of GCV resistance in 10 out of 34 adults treated after PBSCT. 4 However, according to our experience the rapid emergence of GCV resistance in codons 591/603 should not be ignored. 5, 6 Initially, Wolf et al 7 reported on the early emergence of GCV resistance in children with primary combined immunodeficiency (CID) after T cell-depleted BMT in four out of six cases. Recently, we also reported three children who developed GCV resistance after a short time of GCV therapy and we presented detailed longitudinal analyses of HCMV infection and resistance development after T cell depleted PBSCT. 6 General risk factors for resistance development, such as intense immunosuppression and prolonged exposure to GCV could not fully explain the rapid resistance development in our cases or in the patients with CID. 7 
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Because only limited information exists about the conditions of resistance development in the BMT setting and because the dynamics of GCV resistance development in vivo is still unclear, we retrospectively correlated the recovery of T cell subtypes with the development of GCV-resistance mutations, mapped to the phosphotransferase (UL97) gene.
Patients, materials and methods
The cases presented belong to a sequence of 79 pediatric patients who received positively selected, highly purified CD34
+ peripheral blood stem cells transplanted between August 1995 and March 2000.
Patients with GCV resistance
Recently, we reported three children with drug-resistant human cytomegalovirus infection after allogeneic stem cell transplantation resulting in different clinical outcomes. 6 
Control Groups A, B, C
Controls consisted of eight HCMV IgG-negative patients without any infection (A), four HCMV PCR positive patients with viral leukoDNAemia and asymptomatic HCMV infection (B), and three patients with viral leukoDNAemia and HCMV disease (C). In order to obtain homogenous control groups (A and B), only patients with the same diagnosis (acute leukemia) and long follow-up were included. All three patients of group C suffered from HCMV pneumonia.
HCMV-monitoring, antiviral therapy and resistance screening
All patients were monitored weekly for HCMV infection using PCR and virus culture from leukocytes, plasma, urine and throat washes. 8 Semi-quantitative limiting dilution nested PCR from native plasma was performed whenever HCMV-plasma-DNAemia was detected. 9 Antiviral therapy with GCV was initiated (initiation 5 mg/kg/ twice a day, maintenance 5 mg/kg/day), when two consecutive PCRs from leukocytes were positive. GCV-resistant infection was alternatively treated with PFA (3 ϫ 40/3 ϫ 50 mg/kg/day) or CDV (5 mg/kg weekly). 6 Due to clinical suspicion, phenotypic 10 and genotypic 5 resistance screening was performed from all specimens available.
Drug sensitivity testing
Cell-associated virus isolates were tested for phenotypic drug resistance with a simplified cell-associated plaque reduction assay, and the dose of antiviral therapy required for 50% inhibition of plaque formation (IC 50 ) was determined using Probit analysis. 10 Ganciclovir, cidofovir and foscarnet resistance was defined as IC 50 
Restriction analysis in the UL97 gene
Presence of mutations in UL97 was screened in DNA specimens and virus isolates by restriction analysis in codons 460, 520, 591, 592, 594, 595 and 603 as reported. 5 For examination of codons 460 and 520, a 266 bp PCR fragment was digested using restriction enzymes NlaIII and AluI. For codons 591, 592, 594 and 603, a 189 bp PCR fragment was digested using endonucleases HaeIII, FseI, Hin6I and AvaII. For codon 595, a 121 bp fragment was digested using TaqI and MseI.
Sequencing analysis
Sequencing analysis of codons 439 to 696 of the UL97 gene 5 and codons 365 to 1084 of the UL54 gene (viral polymerase) were performed by using BigDye-Terminator chemistry on an ABI 310 machine (PE Applied Biosystems, Weiterstadt, Germany). 6 
Flow cytometry
Blood samples were stained with anti-CD3-FITC, anti-CD4-FITC, anti-CD8-PE, anti-CD19-PE and a nonbinding isotype IgG control (Becton Dickinson, Heidelberg, Germany). FACS analysis was performed on FACScan or FACS CALIBUR instruments (Becton Dickinson). Debris, dead cells, cell aggregates and platelets were excluded by gating on forward scatter and sideward scatter. A minimum of 10 000 events was used for assessment. FACS analyses were performed monthly.
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Results
Figures 1-3 show the correlation between the first appearance of genotypic GCV resistance and cellular immune recovery in patients 1 to 3. Genotypic resistance is indicated by the UL97 mutations found in leukocytes or plasma/serum being confirmed by phenotypic resistance detection in viral isolates from urine (Nos 1 and 2) and throat washes (No. 3). The last negative and the first positive detection of UL97 mutations in leukocytes or plasma/serum are marked by dotted lines. An overview of resistance mutations found in different specimens is shown in Table 1 . Figure 4 shows the immune recovery of control groups A, B and C.
Patients without any infection (A) in general, showed accelerated immune reconstitution patterns of T cells when compared to patients with asymptomatic HCMV infection (B) or with HCMV disease (C), as shown in detail in Figure 4 . In group A, the CD3 + cells (day +30: CD3 + 72 cells/l) recovered earlier than in group B and C (day +120: CD3 + Ͻ10 cells/l, respectively), but finally increased to similar cell counts (CD3 + cells/l on day +180: A = 229, B = 184, C = 230). In group A, the CD3 + cell counts were not higher than 100 cells/l until day +150.
Patient No. 1 ( Figure 1 ) had a lymphocytopenia of the CD4 + (18 cells/l) and CD19 + cells (Ͻ10 cells/l) on day +31 about 2 weeks before the emergence of an UL97 mutation, CD3
+ cells already being elevated (533 cells/l). After the emergence of GCV resistance on day +44, the T cells recovered to extremely high cell counts on day +53 (cells/l, CD3 + : 9262, CD4 + : 3285, CD8 + : 6267), while B cells did not markedly increase (CD19 + : 41). Compared to the control group without any infection (group A) this patient reached extremely elevated immune cell counts after resistance emergence. Remarkably, a high viral DNA-titer in plasma on day +44 and on day +53 was observed also (see Figure 1) . The patient's underlying disease before PBSCT was an innate T cell defect associated with several episodes of disseminated HCMV infection. After PBSCT, he suffered from chronic restrictive lung disease. On day +149, an additional resistance mutation for GCV was uniquely found in a urine isolate (Figure 1) . Thereafter, the patient's pulmonary situation deteriorated and he died at day +170.
Patient No. 2 ( Figure 2 ) exhibited a delayed immune
Bone Marrow Transplantation recovery similar to control groups B and C. On day +61 before the emergence of GCV resistance (day +71), the CD3 + , CD4 + and CD8 + cell counts were extremely low (cells/l, CD3 + : Ͻ10, CD4 + : Ͻ10, CD8 + : Ͻ10). The patient had a prolonged lymphocytopenia developing in the following further UL97 mutations, as well as additional UL54 mutations associated with PFA and CDV resistance. On day +197, after multidrug resistance was manifest, immune cells first appeared elevated (cells/l, CD3 + : 362, CD4 + : 96, CD8 + : 291, CD19 + : 213). The patient was transplanted for AML in second remission with initial hyperleukocytosis and CNS infiltration. He had a disseminated HCMV infection with viral plasma DNAemia during conditioning and died on day +287, suffering from severe HCMV encephalitis. In CSF specimens the UL97 A591V and the UL54 L802M mutation were not found. However a new UL97 mutation P521L, restricted to CSF specimens, could be detected by sequencing analysis and experimental intrathecal GCV administration was not able to prevent further deterioration in this patient.
Patient No. 3 ( Figure 3 ) had a T cell lymphocytopenia on day +72 (cells/l, CD3 + : Ͻ10, CD4 + : Ͻ10, CD8 + : Ͻ10) before the emergence of GCV resistance on day +95. Figure 2 Temporal relation between the emergence of genotypic drug resistance and the cellular immune recovery in patient 2. Donor HCMV negative, host HCMV positive (DϪ/R+); each closed circle (¼) means a weekly administration of cidofovir. *CSF specimens did not contain UL97 A591V and UL54 L802M mutation. However, a new UL97 mutation (P521L) was found, being restricted to CSF specimens. Additional UL97 mutations on day +167 were not persisting. Since day +195 multidrug resistance was genotypically and phenotypically manifest with persisting UL54 mutations.
higher immune cell counts than in group A, as similarly observed in patient 1. In contrast to patient No. 1, patient No. 3 was able to clear resistant virus from blood specimens and to take control of his virus burden. As recently reported, he also did not suffer from HCMV-related symptoms or signs. 6 He was transplanted for AML in first remission, with initial infiltration of the CNS, orbits, pleura and lymph nodes. From day +169 after transplantation the mutation conferring resistance was no longer detectable in sporadically HCMV PCR-positive leukocyte specimens. Remarkably, the first available viral isolate from this patient on day +224 still showed phenotypic and genotypic resistance.
Discussion
Reviewing the literature, there seems to exist a slight accumulation of GCV resistance development in children after T cell-depleted BMT/PBSCT [5] [6] [7] 12 in contrast to the adult BMT setting. 3, 4 As reported, 6 the GCV resistance mutations can emerge rapidly. In one patient it happened within 9 days (Figure 3) . In all three patients immunosuppression after transplantation was not necessary due to the low T cell count in the graft. 6, 11 None of the three patients received extensive GCV therapy until GCV resistance emerged (range: 24 to 53 days after transplantation), compared to reports on organ transplants 2 or AIDS patients. 3 High-risk patients as HCMV seronegative recipients of a seropositive transplant (RϪ/D+) were not present, being found in the context of GCV resistance in lung transplant recipients. 13 All three patients were R+. Therefore, these assumed risk factors cannot be blamed for the development of resistance in the cases presented.
GCV therapy prior to PBSCT/BMT, as observed in patient 1, could be one possible risk factor due to preselection of mutant virus, subsequently followed by a sudden emergence of resistant virus on therapy, with high viral replication rates. This observation, also reported by Wolf et al, might explain why patient 1, being the only one who had GCV pre-therapy (69 days), developed a resistant mutation after a very short period of GCV therapy after PBSCT (24 days).
HCMV-DNAemia and GCV therapy in the very early post-transplant phase of patients 1 and 2 might have also favored the emergence of resistant strains. However, as shown in patient 3, none of these possible risk factors was observed. . After the mutation L595S had disappeared from blood specimens it was again detectable in a throat isolate on day +224. T cell depletion bears the risk of opportunistic infections.
14 Thus, the period in T cell-depleted patients with an assumed lack of functional immune cells may also favor the emergence of drug resistance by uncontrolled virus replication and selection of the fittest mutant strain. 15 This might be a reason why patient 3 developed GCV resistance during immune cell recovery.
Although expected, resistance development did not necessarily correlate with delayed immune recovery. This emphasizes our previous findings that GCV-resistant HCMV infection does not necessarily result in a poor clinical outcome. 6 Interestingly, GCV resistance was detectable by genotypic analysis in all the cases presented in the early phase after PBSCT (range day +44 to day +95 after PBSCT). Furthermore, patient 2 with a prolonged lymphocytopenia developed multidrug resistance within 7 months. To date, this has only been observed in AIDS patients after extensive antiviral therapy of 20 months. Unfortunately, CDV resistance is mostly selected by prolonged GCV therapy. This could also be shown for patient 2.
6 Therefore, our data strongly suggest more stringent resistance screening of DNA specimens from different sites in the early posttransplant phase in children receiving PBSCT that could lead to a timely change of antiviral therapy. This hypothesis is strengthened by a report on a child having T cell-depleted PBSCT and suffering from GCV-and cidofovir-resistant HCMV ventriculoencephalitis. 12 In this report, resistance development was first investigated in CSF specimens on day +220 after PBSCT.
The data presented demonstrate for the first time the rapid emergence of GCV resistance in the context of cellular immune recovery. In contrast to other studies 4 our mutation screening, including RFLP and sequencing of the UL97 and UL54 region, was performed longitudinally without the restriction on certain UL97 codons frequently contributing to GCV resistance. Only such detailed genotypic drug resistance screening will be of use in making valid predictions of the incidence of GCV resistance in a given cohort.
In this study, in patient 1 a high viral DNA titer was observed when T cells were increasing to high cell counts and GCV resistance was emerging. Thus, rapid proliferation of HCMV-specific T cells functionally insufficient in viral defense may be assumed. The lack of HCMV specific T cells may also be a predominant risk factor for resistance emergence. Further detailed analyses of the recovery of functional T cells in the context of HCMV infection, and antiviral therapy in a greater number of children after T cell-depleted PBSCT/BMT with resistance development might lead to a clearer correlation between speed of immune recovery and GCV resistance, and thereby to further understanding of the dynamics of resistance development.
